Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: The health, economic and societal burden of asthma is considerable, and is greatest in patients with severe asthma, particularly when inadequately controlled. Real‐life studies that assess the effectiveness of treatment are of particular interest. Methods: We determined the incremental cost‐effectiveness ratio (ICER) of adding omalizumab to standard therapy using data from the real‐life 1‐year randomized open‐label study (ETOPA) and using Canada as a reference country. Only patients receiving high‐dose ICS plus LABA were included in the analysis, reflecting the EU label for omalizumab. Costs and quality‐adjusted life years (QALYs) gained were used to calculate the ICER for omalizumab (cost/QALY). Probabilistic sensitivity analysis was performed to determine the 95% confidence interval and one‐sided sensitivity analyses were performed. Results: The base case lifetime analysis of standard therapy vs standard therapy plus add‐on omalizumab for the first 5 years, gave an ICER of €31 209. Probabilistic sensitivity analysis indicated that the 95% confidence interval around the ICER was €27 739–€40 840. The ICER range for one‐way sensitivity analyses was €23 762 without discounting to €66 443 without inclusion of asthma‐related mortality. Conclusions: This study demonstrates that add‐on omalizumab therapy is cost‐effective in patients with severe persistent allergic asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Hedgecock, S., Blogg, M., & Cioppa, G. D. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00770.x · Cited by 401
Self-citation
Cited by
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Self-citationOmalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
Farne, H. A., Wilson, A., Powell, C., Bax, L., & Milan, S. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010834.pub3 · Cited by 315
Asthma phenotypes and IgE responses
Froidure, A., Mouthuy, J., Durham, S. R., Chanez, P., Sibille, Y., & Pilette, C. (2016) · European Respiratory Journal · doi:10.1183/13993003.01824-2014 · Cited by 267
Tsabouri, S., Tseretopoulou, X., Priftis, K., & Ntzani, E. E. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.02.001 · Cited by 151
Metadata
- Authors
- Brown, R., Turk, F., Dale, P., & Bousquet, J.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2007-01-15
- Volume
- 62
- Issue
- 2
- Pages
- 149-153
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W1976065152
- Cited by
- 112
- References
- 1
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma. https://app.cochat.ai/papers/10.1111/j.1398-9995.2006.01310.x
- The paper
- Brown, R., Turk, F., Dale, P., & Bousquet, J. (2007). Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy. https://doi.org/10.1111/j.1398-9995.2006.01310.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.